Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium

Abstract

Background

Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras.

Methods

We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites.

Findings

Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES −1.18 years [95% CI −2.05, −0.32]), had fewer respiratory symptoms (RD −0.15 [95% CI −0.33, −0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD −0.35 [95% CI −0.64, −0.07]), lower lymphocyte count (ES −0.16 × 109/uL [95% CI −0.30, −0.01]), lower C-reactive protein (ES −28.5 mg/L [95% CI −46.3, −10.7]), and lower troponin (ES −0.14 ng/mL [95% CI −0.26, −0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES −1.6 years [95% CI −2.5, −0.8]), had less frequent SIRS (RD −0.18 [95% CI −0.30, −0.05]), lower lymphocyte count (ES −0.39 × 109/uL [95% CI −0.52, −0.25]), lower troponin (ES −0.16 ng/mL [95% CI −0.30, −0.01]) and less frequently received anticoagulation therapy (RD −0.19 [95% CI −0.37, −0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (−1.3 days [95% CI −2.3, −0.4]).

Interpretation

Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time.

Citation

F Sperotto, A Gutiérrez-Sacristán, S Makwana, X Li, VN Rofeberg, T Cai, FT Bourgeois, GS Omenn, DA Hanauer, C Sáez, CL Bonzel, E Bucholz, A Dionne, MD Elias, N García-Barrio, TG González, RW Issitt, KF Kernan, J Laird-Gion, SE Maidlow, KD Mandl, TM Ahooyi, C Moraleda, M Morris, KL Moshal, M Pedrera-Jiménez, MA Shah, AM South, A Spiridou, DM Taylor, G Verdy, S Visweswaran, X Wang, Z Xia, JM Zachariasse, JR Aaron, A Adam, G Agapito, A Albayrak, G Albi, M Alessiani, A Alloni, DF Amendola, F Angoulvant, LL Anthony, BJ Aronow, F Ashraf, A Atz, P Avillach, VA Panickan, PS Azevedo, R Badenes, J Balshi, A Batugo, BR Beaulieu-Jones, BK Beaulieu-Jones, DS Bell, A Bellasi, R Bellazzi, V Benoit, M Beraghi, JL Bernal-Sobrino, M Bernaux, R Bey, S Bhatnagar, A Blanco-Martínez, M Boeker, CL Bonzel, J Booth, S Bosari, FT Bourgeois, RL Bradford, GA Brat, S Bréant, NW Brown, R Bruno, WA Bryant, M Bucalo, E Bucholz, A Burgun, T Cai, M Cannataro, A Carmona, AM Cattelan, C Caucheteux, J Champ, J Chen, KY Chen, L Chiovato, L Chiudinelli, K Cho, JJ Cimino, TK Colicchio, S Cormont, S Cossin, JB Craig, JL Cruz-Bermúdez, J Cruz-Rojo, A Dagliati, M Daniar, C Daniel, P Das, B Devkota, A Dionne, R Duan, J Dubiel, SL DuVall, L Esteve, H Estiri, S Fan, RW Follett, T Ganslandt, N García-Barrio, LX Garmire, N Gehlenborg, EJ Getzen, A Geva, RS Goh, TG González, T Gradinger, A Gramfort, R Griffier, N Griffon, O Grisel, A Gutiérrez-Sacristán, PH Guzzi, L Han, DA Hanauer, C Haverkamp, DY Hazard, B He, DW Henderson, M Hilka, YL Ho, JH Holmes, JP Honerlaw, C Hong, KM Huling, MR Hutch, RW Issitt, AS Jannot, V Jouhet, MK Kainth, KF Kate, R Kavuluru, MS Keller, CJ Kennedy, KF Kernan, DA Key, K Kirchoff, JG Klann, IS Kohane, ID Krantz, D Kraska, AK Krishnamurthy, S L’Yi, J Leblanc, G Lemaitre, L Lenert, D Leprovost, M Liu, NH Will Loh, Q Long, S Lozano-Zahonero, Y Luo, KE Lynch, S Mahmood, SE Maidlow, A Makoudjou, S Makwana, A Malovini, KD Mandl, C Mao, A Maram, M Maripuri, P Martel, MR Martins, JS Marwaha, AJ Masino, M Mazzitelli, DR Mazzotti, A Mensch, M Milano, MF Minicucci, B Moal, TM Ahooyi, JH Moore, C Moraleda, JS Morris, M Morris, KL Moshal, S Mousavi, DL Mowery, DA Murad, SN Murphy, TP Naughton, CT Breda Neto, A Neuraz, J Newburger, KY Ngiam, WF Njoroge, JB Norman, J Obeid, MP Okoshi, KL Olson, GS Omenn, N Orlova, BD Ostasiewski, NP Palmer, N Paris, LP Patel, M Pedrera-Jiménez, AC Pfaff, ER Pfaff, D Pillion, S Pizzimenti, T Priya, HU Prokosch, RA Prudente, A Prunotto, V Quirós-González, RB Ramoni, M Raskin, S Rieg, G Roig-Domínguez, P Rojo, N Romero-Garcia, P Rubio-Mayo, P Sacchi, C Sáez, E Salamanca, MJ Samayamuthu, LN Sanchez-Pinto, A Sandrin, N Santhanam, JCC Santos, FJ Sanz Vidorreta, M Savino, ER Schriver, P Schubert, J Schuettler, L Scudeller, NJ Sebire, P Serrano-Balazote, P Serre, A Serret-Larmande, MA Shah, ZS Hossein Abad, D Silvio, P Sliz, J Son, C Sonday, AM South, F Sperotto, A Spiridou, ZH Strasser, AL Tan, BWQ Tan, BWL Tan, SE Tanni, DM Taylor, AI Terriza-Torres, V Tibollo, P Tippmann, EM Toh, C Torti, EM Trecarichi, AK Vallejos, G Varoquaux, ME Vella, G Verdy, JJ Vie, S Visweswaran, M Vitacca, KB Wagholikar, LR Waitman, X Wang, D Wassermann, GM Weber, M Wolkewitz, S Wong, Z Xia, X Xiong, Y Ye, N Yehya, W Yuan, JM Zachariasse, JJ Zahner, A Zambelli, HG Zhang, D Zöller, V Zuccaro, C Zucco, JW Newburger, P Avillach. “Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortium”, eClinicalMedicine 64:102212 (2023). doi:10.1016/j.eclinm.2023.102212